ProCE Banner Activity

RELATIVITY-047: OS and ORR by Key Subgroups in Patients With Advanced Melanoma Receiving First-line Relatlimab + Nivolumab vs Nivolumab Alone

Slideset Download
Conference Coverage
Relatlimab + nivolumab was favored over nivolumab alone across key subgroups for PFS, OS, and ORR in previously untreated patients with advanced melanoma.

Released: June 09, 2022

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

BMS

Daiichi Sankyo Inc

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation

Seagen and Genmab